| Type | Public |
| HQ | San Francisco, US |
| Founded | 1990 |
| Size (employees) | 509 (est)+9% |
| Website | nektar.com |
Nektar Therapeutics was founded in 1990 and is headquartered in San Francisco, US
Report incorrect company information
Viewing summary data as a guest
Sign up for free to see all dataKey People/Management at Nektar Therapeutics
Robert Chess
Chairman of the Board
Jillian Thomsen
Senior Vice President, Finance and Chief Accounting Officer
Dorian Hirth
Senior Vice President, Human Resources and Facilities Operations
Timothy Riley
Senior Vice President, Technology Assessment and Quality Assurance
Report incorrect company information
Nektar Therapeutics Office Locations
Nektar Therapeutics has offices in San Francisco, Huntsville and Hyderabad
San Francisco, US (HQ)
455 Mission Bay Boulevard South
Huntsville, US
1112 Church Street
Hyderabad, IN
Sy.Nos.101/2 Genome Valley Lalgadi Malakpet Shameerpet Mandal Rangareddy District Hyderabad
Report incorrect company information
Nektar Therapeutics Financials and Metrics
Nektar Therapeutics Revenue
Nektar Therapeutics's revenue was reported to be $307.71 m in FY, 2017
| USD | |
|---|---|
Revenue (Q3, 2018) | 27.8m |
Gross profit (Q3, 2018) | 23.0m |
Gross profit margin (Q3, 2018), % | 82.8% |
Net income (Q3, 2018) | (96.1m) |
EBIT (Q3, 2018) | (98.6m) |
Market capitalization (9-Nov-2018) | 5.9b |
Closing stock price (9-Nov-2018) | 34.0 |
Cash (30-Sep-2018) | 222.3m |
Nektar Therapeutics's current market capitalization is $5.9 b.
Annual
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 60.9m | 19.8m | 28.5m | 132.9m | 108.8m | 22.7m | 60.0m | 58.9m | 32.8m | 36.3m | 24.7m | 34.6m | 152.9m | 38.0m | 1.1b | 27.8m |
Cost of goods sold | 12.9m | 7.9m | 5.1m | 9.2m | 8.4m | 10.5m | 6.8m | 8.9m | 7.7m | 7.0m | 6.1m | 9.0m | 5.7m | 6.6m | 5.5m | 4.8m |
Gross profit | 48.0m | 11.9m | 23.4m | 123.7m | 100.4m | 12.1m | 53.2m | 50.0m | 25.1m | 29.3m | 18.6m | 25.6m | 147.3m | 31.4m | 1.1b | 23.0m |
Gross profit Margin, % | 79% | 60% | 82% | 93% | 92% | 54% | 89% | 85% | 76% | 81% | 75% | 74% | 96% | 83% | 99% | 83% |
Annual
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 65.4m | 32.4m | 30.7m | 32.0m | 129.5m | 20.9m | 18.8m | 72.5m | 55.7m | 63.3m | 23.5m | 16.1m | 38.0m | 34.8m | 911.1m | 222.3m |
Accounts Receivable | 4.6m | 1.9m | 3.0m | 46.1m | 2.9m | 3.7m | 3.0m | 39.7m | 27.8m | 14.2m | 1.6m | 4.1m | 3.3m | 15.6m | 35.3m | 31.9m |
Inventories | 15.1m | 12.9m | 14.1m | 11.7m | 12.5m | 10.1m | 10.4m | 11.3m | 10.3m | 10.8m | 13.0m | 11.0m | 13.7m | 10.7m | 11.9m | 13.3m |
Current Assets | 207.9m | 304.8m | 298.2m | 324.1m | 347.3m | 302.2m | 286.4m | 344.8m | 318.3m | 282.5m | 381.0m | 288.2m | 382.8m | 336.0m | 1.9b | 1.5b |
Annual
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (114.4m) | (46.2m) | (78.8m) | (8.2m) | 33.8m | (18.8m) | (27.0m) | (19.5m) | (68.1m) | (111.3m) | (63.9m) | (123.7m) | (62.9m) | (95.8m) | 875.7m | 779.5m |
Depreciation and Amortization | 10.9m | 3.3m | 6.5m | 9.7m | 3.0m | 5.8m | 9.1m | 3.7m | 7.6m | 11.5m | 4.0m | 8.3m | 12.1m | 2.5m | 5.1m | 7.8m |
Inventories | 3.2m | 580.0k | (659.0k) | 1.8m | 441.0k | 2.8m | 2.6m | 96.0k | 1.1m | 592.0k | (1.9m) | 101.0k | (2.5m) | 51.0k | (1.2m) | (2.6m) |
Accounts Payable | 697.0k | (6.1m) | (1.8m) | (3.7m) | 2.2m | (10.0k) | (525.0k) | (34.0k) | 17.0k | 4.8m | 4.1m | 3.2m | 5.7m | 6.5m | 5.8m | 2.6m |
| USD | Y, 2018 |
|---|---|
Financial Leverage | 1.3 x |
Report incorrect company information
Nektar Therapeutics Online and Social Media Presence
822 Twitter followers
Nektar Therapeutics has 822 Twitter Followers. The number of followers has increased 1.8% month over month and increased 8.4% quarter over quarter
Report incorrect company information
Nektar Therapeutics News and Updates
November 09, 2018
Nektar Therapeutics Presents New Clinical and Preclinical Data for its Immuno-Oncology Pipeline at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting
SAN FRANCISCO, Nov. 9, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today a presentation of new clinical and preclinical data for its I-O pipeline at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting. New clinical study results from the PIVOT-02 Phase ...
November 09, 2018
Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Filed Against Nektar Therapeutics - NKTR
RADNOR, Pa., Nov. 9, 2018 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP alerts investors that a securities fraud class action lawsuit has been filed against Nektar Therapeutics (Nasdaq: NKTR) ("Nektar") on behalf of purchasers of Nektar securities between November 11, ...
November 08, 2018
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Nektar Therapeutics To Contact The Firm
NEW YORK, Nov. 8, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ:NKTR) of the December 31, 2018 deadline to seek the role of lead plaintiff in a federal securities class action ...
November 07, 2018
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nektar Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - NKTR
NEW YORK, Nov. 7, 2018 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Nektar Therapeutics, Inc. ("Nektar" or the "Company") (NASDAQ: NKTR) and certain of its officers. The class action, filed in United States District Court, Northern District of ...
November 02, 2018
NEKTAR INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Nektar Therapeutics To Contact The Firm
NEW YORK, Nov. 2, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ:NKTR). If you invested in Nektar stock or options and would like to discuss your legal...
October 03, 2018
Nektar Therapeutics (NKTR) Investigated by Block & Leviton LLP For Violations of Federal Securities Laws
BOSTON, Oct. 3, 2018 /PRNewswire/ -- Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, is investigating whether Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) and certain of its officers and directors violated federal...
Report incorrect company information
Nektar Therapeutics Blogs
November 14, 2018
Nektar Appoints Wei Lin, M.D., as Senior Vice President of Clinical Development and Head of Nektar's Oncology Programs
Nektar Appoints Wei Lin, M.D., as Senior Vice President of Clinical Development and Head of Nektar's Oncology Programs
Content Import
Wed, 11/14/2018 - 09:04
Nektar Appoints Wei Lin, M.D., as Senior Vice President of Clinical Development and Head of Nektar's Oncology Programs
…
November 07, 2018
Nektar Therapeutics Reports Financial Results for the Third Quarter of 2018
SAN FRANCISCO , Nov. 7, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2018 . Cash and investments in marketable securities at September 30, 2018 were $2.0 billion as compared to $353.2 million at December 31,
November 06, 2018
New Clinical Oncology Collaboration Between Nektar and Pfizer to Evaluate Combination of NKTR-214, a CD122-Biased Agonist, with Avelumab and Talazoparib or Enzalutamide in Multiple Cancers
SAN FRANCISCO , Nov. 6, 2018 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced that it has entered into an oncology clinical collaboration with Pfizer Inc. (NYSE:PFE) to evaluate several combination regimens in multiple cancer settings, including metastatic castration-resistant prostate
November 06, 2018
Nektar Therapeutics to Host Webcast Conference Call with Melanoma Specialists for Analysts & Investors During 2018 Society for Immunotherapy of Cancer 33rd Annual Meeting
Nektar Therapeutics to Host Webcast Conference Call with Melanoma Specialists for Analysts & Investors During 2018 Society for Immunotherapy of Cancer 33rd Annual Meeting
Content Import
Tue, 11/06/2018 - 08:05
Nektar Therapeutics to Host Webcast Conference Call with Melanoma Specialist…
October 30, 2018
Nektar to Announce Financial Results for the Third Quarter 2018 on Wednesday, November 7, 2018, After Close of U.S.-Based Financial Markets
SAN FRANCISCO , Oct. 30, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter on Wednesday, November 7, 2018 , after the close of U.S.-based financial markets. Howard Robin , president and chief executive officer, will host a conference
October 02, 2018
Nektar Therapeutics Announces Ten Abstracts Accepted for Presentation at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting
SAN FRANCISCO , Oct. 2, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that ten clinical and preclinical data presentations across its immuno-oncology portfolio will be presented at the upcoming Society for Immunotherapy of Cancer ( SITC ) Annual Meeting, which is being
Nektar Therapeutics Company Life and Culture
Report incorrect company information
Nektar Therapeutics Frequently Asked Questions
When was Nektar Therapeutics founded?
Nektar Therapeutics was founded in 1990.
Who are Nektar Therapeutics key executives?
Nektar Therapeutics's key executives are Robert Chess, Jillian Thomsen and Dorian Hirth.
How many employees does Nektar Therapeutics have?
Nektar Therapeutics has 509 employees.
What is Nektar Therapeutics revenue?
Latest Nektar Therapeutics annual revenue is $307.7 m.
What is Nektar Therapeutics revenue per employee?
Latest Nektar Therapeutics revenue per employee is $604.5 k.
Who are Nektar Therapeutics competitors?
Competitors of Nektar Therapeutics include Northwest Biotherapeutics, Merrimack Pharmaceuticals and TESARO.
Where is Nektar Therapeutics headquarters?
Nektar Therapeutics headquarters is located at 455 Mission Bay Boulevard South, San Francisco.
Where are Nektar Therapeutics offices?
Nektar Therapeutics has offices in San Francisco, Huntsville and Hyderabad.
How many offices does Nektar Therapeutics have?
Nektar Therapeutics has 3 offices.